Pfizer: new Chief Scientific Officer on January 1
(CercleFinance.com) - Pfizer announces the appointment of Chris Boshoff as Chief Scientific Officer and President, Research and Development, effective January 1, 2025, succeeding Mikael Dolsten, whose departure from the group was announced earlier this year.
Currently Head of Oncology, Chris Boshoff will remain a member of the Pfizer management team in his new position, overseeing all R&D functions across all therapeutic areas.
Roger Dansey will take on the role of interim Head of Oncology, until a permanent successor is appointed. Finally, Johanna Bendell will join Pfizer from Roche in 2025 as Head of Oncology Development.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Currently Head of Oncology, Chris Boshoff will remain a member of the Pfizer management team in his new position, overseeing all R&D functions across all therapeutic areas.
Roger Dansey will take on the role of interim Head of Oncology, until a permanent successor is appointed. Finally, Johanna Bendell will join Pfizer from Roche in 2025 as Head of Oncology Development.
Copyright (c) 2024 CercleFinance.com. All rights reserved.